http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
동맥혈 칼슘 자극 검사로 진단된 국소성 췌도 세포 증식증 1예
윤진훈,안규정,주영실,김병준,김성훈,권계형,정명아,양진수,정인수,김충현,조성범,이태석,김은경 대한내분비학회 2001 Endocrinology and metabolism Vol.16 No.4
We report a 40-year-old female patient with clinical findings suggestive of insulinoma. Although imaging studies did not reveal any tumors in the pancreas, a selective arterial calcium stimulation test (SACI), procedurally simpler and more effective than transhepatic pancreatic venous sampling, was performed. And then near total pancreatectomy was carried out because the possibility of small insulinoma could not be completely excluded. Grossly, the surgically removed pancreas did not reveal any tumors. However, the pancreas exhibited islets cell hyperplasia. To our knowledge, this is the first reported authentic case in a Korean adult of islet-cell hyperplasia diagnosed by selective arterial calcium stimulation test
安榮根,安文圭,安年衡 圓光大學校 1972 論文集 Vol.6 No.-
The concentration of mercury in the water, rice, fishes and shell fishes, paddy soil and in the sludges of The Mankyoung River which flows through the center of the Mankyoung Field and empties into the west sea was measured. The contents ranged from trace to 0.015 ppm in the water, 0.085 to 0.20ppm in the rice, 0.09 to 0.35 ppm in the fishes and shell fishes, 0.30 to 0.72 ppm in the paddy soil and from 0.12 to 0.58 ppm in the sludges.
IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling.
Jung, Seung-Youn,Yi, Jae Youn,Kim, Mi-Hyoung,Song, Kyung-Hee,Kang, Seong-Mook,Ahn, Jiyeon,Hwang, Sang-Gu,Nam, Ky-Youb,Song, Jie-Young National Hellenic Research Foundation 2015 Oncology reports Vol.34 No.5
<P>Triple-negative breast cancer (TNBC) is an aggressive cancer with a poor prognosis due to its epithelial???to-mesenchymal transition (EMT) phenotype. Cancer patients often experience several detrimental effects of cancer treatment, such as chemoresistance, radioresistance and the maintenance of cancer stem cells due to EMT. Thus, EMT signaling is considered to be a valuable therapeutic target for cancer treatment, and its inhibition is being attempted as a new treatment option for TNBC patients. Previously, we showed that 3-(2-chlorobenzyl)-1,7-dimethyl-1H-imidazo[2,1-f]purine???2,4(3H,8H)-dione (IM-412) inhibits transforming growth factor-관 (TGF-관)-induced differentiation of human lung fibroblasts through both Smad-dependent and??-independent pathways. In the present study, we examined the inhibitory effect of IM-412 on EMT pathways and invasiveness in TNBC cells since the TGF-관 signaling pathway is a typical signaling pathway that functions in EMT. IM-412 not only potently suppressed the migration and invasion of MDA-MB-231??cells, but also lowered the expression of mesenchymal markers and EMT-activating transcription factors in these cells. IM-412 inhibited the activation of several signaling proteins, including Smad2/Smad3, p38MAPK, Akt and JNK, and it also attenuated the phosphorylation of FGFR1 and FGFR3. Collectively, our findings suggest that the synthetic compound IM-412 suppressed the EMT process in MDA-MB-231??cells and thereby effectively inhibited the migration and invasion of these cancer cells. Thus, IM-412 could serve as a novel therapeutic agent for malignant cancers.</P>
만성 요통 변증 설문지 개발을 위한 전문가 Delphi 조사
안민윤 ( Min Youn Ahn ),송윤경 ( Yun Kyung Song ),고성규 ( Seong Gyu Ko ),임형호 ( Hyoung Ho Lim ) 한방재활의학과학회 2013 한방재활의학과학회지 Vol.23 No.4
ObjectivesThe aim of this study is to contribute to developing questionnaire for pattern identification of chronic low back pain using delphi method. MethodsThe questionnaire which includes symptoms and signs of chronic low back pain is studied by delphi method. Seven experts of Korean medicine, especially of re-habilitation medicine participated in delphi examination. Delphi examination was carried out through evaluating and correcting the questionnaire by e-mail.ResultsBy the Delphi method and score evaluation, 20 items of the initial copy of ques-tionnaire are chosen for pattern identification of chronic low back pain.ConclusionsBy the delphic method among experts, a reference questionnaire for pat-tern identification of chronic low back pain was suggested. Further research is necessary for modification of questionnaire by statistics and certification by clinical trial research. (J Korean Med Rehab 2013;23(4):143-158)
Young Jin Youn,Sang-Yong Yoo,Jun-Won Lee,Sung-Gyun Ahn,Seung-Hwan Lee,Junghan Yoon,Jae Hyoung Park,Woong Gil Choi,Sungsoo Cho,Sang-Wook Lim,Yang Soo Jang,Ki Hwan Kwon,이남호,Joon Hyung Doh,Woong Chol Kan 대한심장학회 2020 Korean Circulation Journal Vol.50 No.4
Background and Objectives: Recently, Genoss drug-eluting stent (DES)™ stent comprising cobalt-chromium platform with an ultrathin strut thickness, sirolimus, and an abluminal biodegradable polymer was developed. Owing to the lack of substantial evidence for the safety and efficacy of this stent, we report 12-month results of the Genoss DES™ stent. Methods: We analyzed subjects who were eligible for a 12-month follow-up from the ongoing Genoss DES™ registry, which is a prospective, single-arm, observational, multicenter trial to investigate the clinical outcomes after the successful Genoss DES™ stent implantation among all-comers. The primary endpoint was a device-oriented composite outcome, defined as cardiac death, target vessel-related myocardial infarction, and target lesion revascularization at 12-month follow-up. Results: Among 622 subjects, the mean age of subjects was 66.5±10.4 years, 70.6% were males, 67.5% had hypertension, and 38.3% had diabetes. The implanted stent number, diameter, and length per patient were 1.5±0.8, 3.1±0.4 mm, and 36.0±23.3 mm, respectively. At 12-month clinical follow-up, the primary endpoint occurred only in 4 (0.6%) subjects. Conclusions: The novel Genoss DES™ stent exhibited excellent safety and efficacy in real-world practice.
Hyun-Kyoung Ahn,Youn-Su Kim,Byung-Gi Park,In-Hyoung Rhee 대한상하수도학회 2021 상하수도학회지 Vol.35 No.6
전자 및 화학 산업의 초순수 생산 및 원자력 발전소의 부식 제어를 위해 이온교환 수지탑의 성능 파악이 필수적이다. 따라서 본 연구에서는 4종의 H 및 ETAH 형 양이온 교환수지가 채워진 양이온 및 혼상 이온교환수지탑에 미량의 NaCl를 포함하는 에탄올아민(ETA) 및 암모니아(NH3) 용액을 주입하여 양이온 파과특성을 조사하였다. 조사 결과, 주성분인 ETAH+ 및 NH4 +와 달리, 미량성분인 Na+는 (이론적교환용량의 3배 이상) 시험기간 동안 수지탑 출구에서 파과 및 오버슈팅 현상이 나타나지 않았다. H형 수지탑의 파과현상은 ETAH+ 및 NH4 +가 순서대로 일어났고, 오버슈팅은 NH4 +가 파과할때 ETAH+에 대해서 발생했다. 파과영역의 너비로 결정되는 상대적 선택도는 NH4 +가 ETAH+보다 최대 51.5 % 더 높았다. 유입수 Na+ 농도가 높을수록, 선택도는 감소하고 오버슈팅 현상은 증가하였다. 이온교환 수지의 고유 특성을 개선하여 감소시킬 수 있는 Na+ 누출은, ETAH형에서 높았고 4종의 양이온수지에 대해 동일하지 않은 것으로 조사되었다. Ion exchange (IX) performance on the exchanger bed is essentially evaluated for the generation of ultrapure water in electronics and chemical industries and for the corrosion control in nuclear power plants. The breakthrough characteristics of IX bed with multi-component were investigated with both cation- and mixed-IX beds of H- and ETAH-form for four kinds of cation exchange resins by using the combined solution of ethanolamine (ETA) and ammonia (NH3) at trace NaCl. Unlike major components (ETAH+ and NH4 +), the phenomena of breakthrough and overshooting at bed outlet were not observed by Na+ over the test period (> 3 times theoretical exchange capacity of IX bed). The breakthrough from H-form resin bed was sequentially reached by ETAH+ and NH4 +, while the overshooting was observed for ETAH+ at the breakthrough of NH4 +. NH4 + was 51.5% higher than ETAH+ in terms of the relative selectivity determined with the width of breakthrough zone. At the increased concentration of Na+ at bed inlet, the selectivity and the overshooting were decreased and increased, respectively. Na+ leakage was higher from ETAH-form resin bed and was not identical for four kinds of cation-exchange resins, which may be reduced by improving the intrinsic property of IX resin.
Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice
( Young Jin Youn ),( Jun-won Lee ),( Sung Gyun Ahn ),( Seung-hwan Lee ),( Junghan Yoon ),( Jae Hyoung Park ),( Sang-yong Yoo ),( Woong Chol Kang ),( Nam Ho Lee ),( Ki Hwan Kwon ),( Joon Hyung Doh ),( 대한내과학회 2023 The Korean Journal of Internal Medicine Vol.38 No.5
Background/Aims: The Genoss DES™ is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DES™ in all-comer patients undergoing percutaneous coronary intervention. Methods: The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DES™ implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months. Results: A total of 1,999 patients (66.4 ± 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 ± 0.8, 3.1 ± 0.5 mm, and 37.0 ± 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%. Conclusions: In this real-world registry, the Genoss DES™ demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DES™ may be a viable treatment option for patients with coronary artery disease.